Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease

Chia Siang Kow; Syed Shahzad Hasan

doi:10.1007/s00296-020-04715-0

Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	2117-2118
Number of pages	2
Journal	Rheumatology International
Volume	40
Issue number	12
Early online date	12 Oct 2020
DOIs	https://doi.org/10.1007/s00296-020-04715-0
Publication status	Published - 1 Dec 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00296-020-04715-0Licence: Unspecified

Cite this

@article{ad4833ef06994bcd833a84a4493b2b08,

title = "Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease",

keywords = "Rituximab, COVID-19, Systemic rheumatic disease",

author = "Kow, \{Chia Siang\} and Hasan, \{Syed Shahzad\}",

year = "2020",

month = dec,

day = "1",

doi = "10.1007/s00296-020-04715-0",

language = "English",

volume = "40",

pages = "2117--2118",

journal = "Rheumatology International",

issn = "0172-8172",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "12",

}

TY - JOUR

T1 - Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease

AU - Kow, Chia Siang

AU - Hasan, Syed Shahzad

PY - 2020/12/1

Y1 - 2020/12/1

KW - Rituximab

KW - COVID-19

KW - Systemic rheumatic disease

UR - https://www.scopus.com/pages/publications/85092386047

U2 - 10.1007/s00296-020-04715-0

DO - 10.1007/s00296-020-04715-0

M3 - Letter

C2 - 33044704

SN - 0172-8172

VL - 40

SP - 2117

EP - 2118

JO - Rheumatology International

JF - Rheumatology International

IS - 12

ER -

Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease

UN SDGs

Access to Document

Other files and links

Sharing the evidence to help tackle COVID-19

Cite this

Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease

UN SDGs

Access to Document

Other files and links

Press/Media

Sharing the evidence to help tackle COVID-19

Cite this